1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Huron Consulting Group's Board elected Dr. L. Thomas Richards as a director effective July 23, 2026, serving until the 2027 Annual Meeting. He was also appointed to three board committees, and the filing describes his background in life sciences, healthcare and M&A advisory. The filing describes a routine board addition with no change to financial results or guidance.
Dr. L. Thomas Richards elected director effective July 23, 2026, to serve until the 2027 Annual Meeting of Stockholders
Appointed to the Nominating and Corporate Governance, Finance and Capital Allocation, and Technology and Information Security committees
Annual cash retainer of $80,000, plus $7,500 per committee, and a restricted stock grant of $180,000 annually, prorated to half for 2026, granted August 1, 2026
Hasbro said President of Wizards of the Coast John Hight will stay in his current role through September 1, 2026, then become an Advisor reporting to the CEO until September 2, 2027, helping onboard a successor. The filing does not name a successor. His $800,000 base salary is unchanged, but he will not receive a fiscal 2027 bonus or new equity awards during the term.
Transition Agreement with John Hight is effective July 27, 2026.
Hight remains President of Wizards of the Coast through September 1, 2026.
From September 2, 2026 to September 2, 2027, he serves as Advisor and reports to the CEO.
Base salary stays at $800,000 annualized; no fiscal 2027 bonus and no new equity grants during the term.
Customers Bancorp and Chief Financial Officer Mark McCollom signed a First Amended Employment Agreement on July 24, 2026, replacing his June 10, 2025 agreement. The amendment adds a 12-month non-compete, requires a release of claims for severance, and sets a 45-day notice period for him to resign, down from 60 days.
Agreement dated July 24, 2026 amends and replaces the employment agreement dated June 10, 2025 with Mark R. McCollom, EVP and CFO.
Term now renews automatically each year unless either party gives at least 60 days' notice before the anniversary date.
Mr. McCollom's notice period to terminate employment shortened from 60 days to 45 days.
New 12-month restrictive covenant bars competing in the Company's Field of Interest in the Restricted Area(s).
Kymera Therapeutics said Chief Medical Officer Jared Gollob resigned on July 27, 2026, for personal reasons, and will stay on as an advisor through December 31, 2026. Terence Rooney, M.D., formerly an immunology leader at Johnson & Johnson, became CMO effective the same day. The change is a senior management transition that leads clinical development for the company's oral immunology pipeline.
Jared Gollob resigned as Chief Medical Officer on July 27, 2026, after eight years with the company, citing personal reasons
Terence Rooney, M.D., succeeds Gollob as CMO effective July 27, 2026
Gollob will continue as an advisor until December 31, 2026
Rooney previously served as Senior Vice President, Portfolio and Asset Management Leader, Immunology, at Johnson & Johnson
Lyft's board appointed Ben Minicucci, chief executive of Alaska Air Group and Alaska Airlines, as a director effective immediately, with a term expiring at the 2027 annual meeting. The filing says the board values his public-company CEO experience, transportation safety expertise and M&A integration background, and it discloses that Lyft and Alaska have a rewards partnership under which Lyft paid Alaska $3.2 million and received $0.16 million in 2025.
Ben Minicucci appointed to Lyft's board on July 23, 2026, as a Class II director
Term expires at Lyft's 2027 Annual Meeting of Stockholders
Lyft paid Alaska $3.2 million and received $0.16 million under the Partnership Agreement in 2025
Minicucci receives standard non-employee director compensation and will sign the standard indemnification agreement
Independent Bank Corporation increased its board from 10 to 11 members and appointed attorney Nathan E. Tagg to fill the new seat, effective July 21, 2026, under the merger agreement for HCB Financial Corp. Mr. Tagg also joins the Audit Committee, which gives a former HCB director a role in overseeing the company's financial reporting.
Board increased from 10 to 11 members; Nathan E. Tagg appointed effective July 21, 2026
Tagg previously served on the HCB Financial Corp. and Highpoint Community Bank boards until the acquisition closed on July 1, 2026
Tagg appointed to the Audit Committee and to the Independent Bank and Highpoint Community Bank boards
Tagg is a partner at Tripp, Tagg & Storrs, Attorneys, where he has practiced since 2009
Cracker Barrel said David Deno, former CEO of Bloomin' Brands, will become President and Chief Executive Officer and join the Board effective August 10, 2026, succeeding Julie Masino, who will also leave the Board. Masino will remain an employee until October 9, 2026 to assist the transition. The filing contains no financial results, so the leadership change is the main development for shareholders.
David Deno, age 69, was CEO of Bloomin' Brands from April 2019 to September 2024 and will become Cracker Barrel's CEO on August 10, 2026.
Deno's employment agreement sets a base salary of $1,000,000, an initial annual bonus target of 125% of base salary, and an initial long-term incentive target of 360% of base salary.
Deno will receive a one-time sign-on award of $200,000 in restricted stock units and $200,000 in stock options, vesting on the third anniversary of the grant date.
Masino's Transition Agreement provides separation payments and equity treatment consistent with a termination without Cause under her July 17, 2023 employment agreement.
Sarepta Therapeutics appointed Michael Severino, M.D., former CEO of Tessera Therapeutics, as chief executive officer effective July 28, 2026, and as a Class I director. Doug Ingram, the current CEO, departs as CEO and board member on that date and will serve as a consultant until December 31, 2026. The filing describes a sign-on equity package with a grant date value of approximately $35 million and a base salary of $1,180,000, which shareholders may track for compensation and leadership continuity.
Michael Severino, M.D., becomes CEO and a director effective July 28, 2026, succeeding Doug Ingram
Sign-on equity grant has an approximate grant date value of $35,000,000, including a $14,000,000 make-whole grant
Severino's employment agreement sets an annual base salary of $1,180,000 and a target bonus of 110% of base salary
Ingram will consult for the company until December 31, 2026, for a monthly fee of $15,000
National Health Investors named Christian Maingot as its first Chief Operations Officer, effective July 27, 2026. He most recently served as CEO of Longview Senior Housing, a Blackstone portfolio company, from May 2022 to April 2026, and has more than 20 years of senior housing experience. The filing sets out his initial compensation, which matters to shareholders because it shows the cost of the new executive role.
Board appointed Maingot on July 22, 2026; role effective July 27, 2026
Initial annual base salary of $415,000
Maximum 2026 performance-based cash bonus of $360,937 (prorated), plus a 2026 equity award with a target value of $375,833 (prorated), split equally between time-based restricted stock and performance-based restricted stock units
Previously spent more than a decade at Brookdale Senior Living, most recently as Senior Vice President of Corporate Development and Strategic Initiatives
Pitney Bowes appointed La Vonda Williams, former CFO of Onegevity Health, to its Board of Directors effective July 21, 2026. She joins the Audit, Governance and Strategic Review Committees, and the filing describes the Strategic Review Committee as formed in connection with the company's previously announced strategic review process.
Appointed to the Board on July 21, 2026, with a $200,000 annual cash retainer plus committee fees under the standard non-management director arrangements
Committee roles: Audit Committee and Governance Committee (additional $20,000 and $12,000 annual cash retainers), and Strategic Review Committee (extra equity grant of $278,000, prorated to $225,446)
Also receives an annual equity grant of $100,000, prorated to $81,095 for her mid-year start, that vests one year later
Filing states no arrangements or understandings tied to her appointment and no related-party transactions under Item 404(a)
Spruce Biosciences appointed Adrian Quartel, M.D., as its Chief Medical Officer on July 27, 2026, replacing Dr. Kirk Ways, who had been serving as interim Chief Medical Officer. Dr. Ways will remain on the Company's Board of Directors. The filing describes Dr. Quartel's experience in pharmaceutical clinical development and rare disease launches, including prior Chief Medical Officer roles at Zevra Therapeutics, Acer Therapeutics and Adamas Pharmaceuticals.
Adrian Quartel, M.D., FFPM, appointed Chief Medical Officer on July 27, 2026
Replaces Dr. Kirk Ways, who had been Interim Chief Medical Officer
Dr. Ways will continue as a member of the Board of Directors
Dr. Quartel previously served as Chief Medical Officer of Zevra Therapeutics, Acer Therapeutics and Adamas Pharmaceuticals
CytomX Therapeutics appointed Dr. Charles Fuchs to its Board of Directors effective July 24, 2026, as a Class II director with a term running to the 2029 annual meeting. The filing says he received an option to buy 118,000 shares of common stock, vesting monthly over three years, which ties part of his pay to the stock price.
Charles Fuchs, M.D., M.P.H., joined the board effective July 24, 2026, as a Class II director.
His initial term expires at the 2029 annual meeting of stockholders.
He received an option to purchase 118,000 shares at the July 24, 2026 closing price, vesting in 1/36th installments monthly.
Cadiz said Chief Financial Officer Stanley Speer will retire effective September 1, 2026, and Jacinto J. Hernandez, currently Executive Vice President of Finance, will become CFO on that date. Speer will serve as an advisor through December 31, 2026, and his separation terms include accelerated vesting of restricted stock units and a new grant tied to the Northern Pipeline project financing.
Stanley E. Speer retires as CFO effective September 1, 2026, and advises the company through December 31, 2026 at $10,000 per month.
Jacinto J. Hernandez, age 47, has an annual base salary of $400,000 and a cash bonus target of 100% of salary.
Hernandez's inducement awards total 800,000 restricted stock units and 800,000 performance stock units, subject to Compensation Committee approval.
XPO, Inc. appointed Michael Kneeland to its board of directors effective July 27, 2026, expanding the board to eight members, seven of whom are independent. Kneeland is non-executive chairman of United Rentals and previously served as its chief executive from 2007 to 2019. The filing reports no financial results or changes to operations, so the appointment is a board governance change.
Kneeland was appointed by the board on July 24, 2026, effective July 27, 2026, and will serve until the 2027 annual meeting of stockholders.
As a non-employee director, he receives an annual cash retainer of $80,000 and an annual RSU grant currently valued at $190,000.
On July 27, 2026, he received a prorated grant of 388 RSUs that vest on January 4, 2027.
The filing states there are no related party transactions with Kneeland reportable under Item 404(a) of Regulation S-K.
SPX Technologies elected Brian Deck, who is CEO of JBT Marel Corporation, as a director effective July 27, 2026, and appointed him to the Audit and Governance & Sustainability Committees. The filing describes this as a board addition with pro-rated director pay, with no change to reported financial results.
Brian Deck elected director effective July 27, 2026; Board elected him July 24, 2026
Appointed to Audit and Governance & Sustainability Committees, effective July 27, 2026
Annual non-employee director pay: $100,000 cash retainer and $150,000 grant-date value of restricted stock units, pro-rated for his service through the 2027 Annual Meeting
Deck currently serves as CEO of JBT Marel Corporation (NYSE: JBTM)
SemiLEDs said its audit committee engaged DLEE Accountancy, Inc. as its new independent registered public accounting firm on July 27, 2026, after the engagement with YCM CPA INC. expired. The company reported no disagreements with YCM and no reportable events during its most recent fiscal year and through the expiration date, and it has asked YCM for a letter confirming whether it agrees with the statements.
Audit committee engaged DLEE Accountancy, Inc. as new independent auditor on July 27, 2026
YCM CPA INC. engagement expired; company reported no disagreements or reportable events with YCM
SemiLEDs requested a letter from YCM to the SEC stating whether it agrees with the company's statements
Filing is signed by Chief Financial Officer Christopher Lee and dated July 27, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.